ERBB3 and breast carcinoma: However, our results demonstrated that HER2Mab not only did not inhibit MCF7 cell proliferation, but it promoted proliferation of the low HER2 expressing MCF7 breast cancer cells in the absence of HER3 ligand NRG1.